Results 31 to 40 of about 581 (153)

Enantioseparation of solriamfetol and its major impurity phenylalaninol by capillary electrophoresis using sulfated gamma cyclodextrin [PDF]

, 2021
R-solriamfetol is a recently approved drug used for the treatment of excessive sleepiness associated with narcolepsy and sleep apnea. Herein, a capillary electrophoretic method was developed, enabling the simultaneous analysis of the API and its S ...
Bianka Várnai, Ida Fejős, Köteles, István, Várnai, Bianka, Szabó, Zoltán-István, Milo Malanga, Szabó, Zoltán István, Szabolcs Béni, Malanga, Milo, Tóth, Gergő, Gergő Tóth, Zoltán István Szabó, Fejős, Ida, István Köteles, Béni, Szabolcs   +14 more
core   +1 more source

Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database [PDF]

Heliyon
He B, Zheng W.
exaly   +2 more sources

Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea [PDF]

, 2022
Objective: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA).
de Vries, Nicolaas, Vinckenbosch, F., Carter, Lawrence P., Asin, Jerryll, Frederick Vinckenbosch, Donjacour, Claire E.H.M., Sebastiaan Overeem, Johannes G. Ramaekers, Donjacour, Claire E. H. M., Hennie Janssen, Grace Wang, Lawrence P. Carter, Lammers, Gert Jan, Carter, L.P., Patty E. Vonk, Ramaekers, J.G., Vinckenbosch, Frederick, Dan Chen, Donjacour, C.E.H.M., Vonk, P.E., Vermeeren, A., Vermeeren, Annemiek, Gert Jan Lammers, Janssen, Hennie, Chen, Dan, Zhou, K.F., Overeem, Sebastiaan; id_orcid, Asin, J., Jerryll Asin, Wang, G., Ramaekers, Johannes G., Kefei Zhou, Annemiek Vermeeren, Claire E. H. M. Donjacour, Overeem, Sebastiaan, Nicolaas de Vries, Lammers, G.J., Zhou, Kefei, Wang, Grace, Vonk, Patty E., Vries, N., Janssen, H., Overeem, S., Chen, D.   +43 more
core   +2 more sources

482 Solriamfetol Titration & AdministRaTion (START): dosing and titration strategies in patients with narcolepsy starting solriamfetol

Sleep, 2021
Abstract Introduction Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor, is approved (US and EU) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnea (OSA) (37.5–150 mg/day).
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +1 more source

The orexin story and orexin receptor antagonists for the treatment of insomnia

Journal of Sleep Research, Volume 32, Issue 6, December 2023., 2023
Summary Insomnia is present in up to one third of the adult population worldwide, and it can present independently or with other medical conditions such as mental, metabolic, or cardiovascular diseases, which highlights the importance of treating this multifaceted disorder.
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse   +3 more
wiley   +1 more source

Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy

Clinical Therapeutics, 2022
Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (in the United States and European Union) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75-150 mg/d) or obstructive sleep apnea (OSA) (37.5-150 mg/d). This study characterized real-world titration strategies for patients with narcolepsy (with or without ...
Michael J, Thorpy, Danielle, Hyman, Gregory S, Parks, Abby, Chen, Catherine, Foley, Beth, Baldys, Diane, Ito, Haramandeep, Singh   +7 more
openaire   +2 more sources

Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression [PDF]

, 2022
Given the high rate of depression associated with narcolepsy or obstructive sleep apnea (OSA), this analysis compared effects of solriamfetol treatment of excessive daytime sleepiness (EDS) in participants with/without a history of depression (DHx+/DHx-).
Babson, Kimberly, Benca, Ruth M, Rosenberg, Russell, Schweitzer, Paula K, Strohl, Kingman P, Krystal, Andrew D, Bujanover, Shay, Malhotra, Atul, Lee, Lawrence   +8 more
core   +1 more source

Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. [PDF]

, 2021
STUDY OBJECTIVES: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union for excessive daytime sleepiness in adults with narcolepsy (75-150 mg/day) or obstructive sleep apnea (OSA; 37.5-150 mg/day).
Mayer, G., Pepin, Jean-Louis, Shapiro, Colin, Weaver, Terri E, Strollo, Patrick J., Ahmed, M., Ahmed, Mansoor, Weaver, T. E., Hedner, Jan, Pepin, J. L., Malhotra, A., Weaver, Terri E., Foldvary-Schaefer, N., Strollo, P. J., Mayer, Geert, Strollo, Patrick, Shapiro, C., Chandler, P., Lee, L., Weaver, Terri, Baladi, M., Chandler, Patricia, Baladi, Michelle, Lee, Lawrence, Sarmiento, K., Bron, M., Hedner, Jan A,, Malhotra, Atul, Foldvary-Schaefer, Nancy, Bron, Morgan, Schwab, R., Schwab, Richard, Strollo, Patrick J, Sarmiento, Kathleen   +33 more
core   +1 more source

Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. [PDF]

, 2021
STUDY OBJECTIVES: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union to treat excessive daytime sleepiness in patients with obstructive sleep apnea (OSA) (37.5-150 mg/day) and narcolepsy (75 ...
Mayer, Geert, Schweitzer, Paula K, Rosenberg, Russell, Strohl, Kingman P, Chandler, Patricia, Baladi, Michelle, Lee, Lawrence, Malhotra, Atul   +7 more
core   +1 more source

1269 Off-Label Use of Solriamfetol In Idiopathic Hypersomnia [PDF]

Sleep, 2020
Abstract Introduction Solriamfetol is a new daily dopamine and norepinephrine reuptake inhibitor indicated for improving daytime wakefulness in adults with obstructive sleep apnea (OSA) and narcolepsy. It was FDA-approved on 3/20/2019.
Talha Memon, Tammy Wong
openaire   +1 more source